Acetylsalicylic acid resistance in long-term follow-up in subjects after myocardial infarction

Abstract

Acetylsalicylic acid (ASA) is widely used as an antiplatelet therapeutic drug in secondary prevention. Despite its recognized benefits in treatment of subjects with cardiovascular (CV) diseases, last years brought many reports on ASA resistance or high-on treatment platelet reactivity (HTPR) despite aspirin treatment. The aim of this study is an evaluation of ASA resistance in long-term control basing on the result of arachidonic acidinduced platelet aggregation in reference to the results obtained during first 9 months of observation